首页> 外国专利> Free functional annexin levels in plasma as a biomarker of cardiovascular risk

Free functional annexin levels in plasma as a biomarker of cardiovascular risk

机译:血浆中游离功能性膜联蛋白水平是心血管疾病风险的生物标志物

摘要

The present invention relates to a method for diagnosing the occurrence of a vascular dysfunction or a vascular injury in a subject, said method comprising a step consisting of determining in a plasma sample obtained from said subject the level of free annexin. The present invention further relates to a method for determining whether a subject is at risk for severe vasculopathy, cardiovascular complications and cardiovascular disease, said method comprising a step consisting of determining in a plasma sample obtained from said subject the level of free annexin. Preferably, the methods further comprise the steps consisting of determining the level of circulating phosphatidylserine positive (PS+) microparticles (MPs) in the plasma sample obtained from said subject and calculating the ratio free annexin / circulating PS+ MPs. The invention also relates to a kit for use in a method according to the invention and to a phosphatidylserine antagonist, for use in a method of treatment of severe vasculopathy, cardiovascular complications and cardiovascular disease in a subject having a decreased level of free annexin as compared to a free annexin reference level, wherein the method comprises a determination of the free annexin level in a plasma sample of said subject. Preferably, a phosphatidylserine antagonist is for use in a method of treatment of severe vasculopathy, cardiovascular complications and cardiovascular disease in a subject having a decreased ratio of free annexin / circulating PS+ MPs as compared to a free annexin / circulating PS+ MPs reference ratio, wherein the method further comprises the steps consisting of determining the circulating PS+ MPs level in said plasma sample and calculating the free annexin / circulating P8+ MPs ratio.
机译:本发明涉及诊断对象中血管功能障碍或血管损伤的发生的方法,所述方法包括确定从所述对象获得的血浆样品中游离膜联蛋白水平的步骤。本发明进一步涉及一种确定受试者是否有严重血管病变,心血管并发症和心血管疾病风险的方法,所述方法包括确定从所述受试者获得的血浆样品中游离膜联蛋白水平的步骤。优选地,所述方法进一步包括以下步骤:确定从所述受试者获得的血浆样品中循环磷脂酰丝氨酸阳性(PS +)微粒(MPs)的水平,并计算游离膜联蛋白/循环PS + MP的比率。本发明还涉及一种用于根据本发明的方法的试剂盒和一种磷脂酰丝氨酸拮抗剂,其用于治疗严重血管病变,心血管并发症和心血管疾病的方法,所述受试者的游离膜联蛋白水平与降低相比有所降低。相对于游离膜联蛋白参考水平的测定,其中所述方法包括测定所述受试者的血浆样品中的游离膜联蛋白水平。优选地,磷脂酰丝氨酸拮抗剂用于治疗严重血管病变,心血管并发症和心血管疾病的受试者,该受试者的游离膜联蛋白/循环PS + MP的参考比例与游离膜联蛋白/循环PS + MP的参考比例相比有所降低,其中该方法进一步包括以下步骤:确定所述血浆样品中循环的PS + MPs水平,并计算游离的膜联蛋白/循环的P8 + MPs比率。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号